Anzeige
Mehr »
Login
Freitag, 29.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
NurExone Biologic: Technisches (täglich, wöchentlich, monatlich) & Analysten "Strong Buy"-Rating!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3ETJD | ISIN: US2312693094 | Ticker-Symbol: CUS0
Frankfurt
28.03.24
17:46 Uhr
10,000 Euro
+0,800
+8,70 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CURIS INC Chart 1 Jahr
5-Tage-Chart
CURIS INC 5-Tage-Chart
RealtimeGeldBriefZeit
9,95010,20028.03.

Aktuelle News zur CURIS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
09.02.Curis reports positive emavusertib trial results, extends cash runway7
09.02.Earnings call: Curis reports Q4 losses, progresses in oncology trials3
08.02.CURIS INC - S-8, Securities to be offered to employees in employee benefit plans1
08.02.CURIS INC - 10-K, Annual Report1
08.02.Curis Inc reports results for the quarter ended in December - Earnings Summary1
08.02.Curis Inc Q4 sales decline336WASHINGTON (dpa-AFX) - Curis Inc (CRIS) announced Loss for fourth quarter of -$11.71 millionThe company's bottom line came in at -$11.71 million, or -$2.03 per share. This compares with -$11.33...
► Artikel lesen
08.02.CURIS INC - 8-K, Current Report-
08.02.Curis, Inc.: Curis Provides Fourth Quarter 2023 Business Update255Emavusertib data presented at ASH showed 3 of 5 patients achieved CR in R/R PCNSL Expansion of clinical sites in US and Europe in progress Cash runway into 2025 Management to host conference call today...
► Artikel lesen
07.02.Curis' Earnings: A Preview2
07.02.Curis Q4 2023 Earnings Preview1
11.01.CURIS INC - 8-K, Current Report7
05.01.XFRA DIVERSE: WIEDERAUFNAHME/RESUMPTION1.126FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME...
► Artikel lesen
05.01.Curis, Inc.: Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)312LEXINGTON, Mass., Jan. 5, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced...
► Artikel lesen
21.12.23CURIS INC - 10-K/A, Annual Report5
05.12.23Curis Inks Deal With Florida University For Emavusertib/Pembrolizumab Combination Study In Melanoma467WASHINGTON (dpa-AFX) - Curis, Inc. (CRIS), Tuesday said it has reached a clinical trial agreement with the University of Florida to study the combination of emavusertib and pembrolizumab in...
► Artikel lesen
17.11.23Curis, Emergent Biosolutions among healthcare movers34
03.11.23Curis, Inc. (CRIS) Q3 2023 Earnings Call Transcript14
02.11.23Earnings call: Curis resumes clinical studies, plans new trials and reports Q3 losses7
02.11.23Curis Inc Q3 Loss decreases, beats estimates511WASHINGTON (dpa-AFX) - Curis Inc (CRIS) announced Loss for third quarter that decreased from last year and missed the Street estimates.The company's bottom line totaled -$12.181 million, or...
► Artikel lesen
02.11.23Curis Inc reports results for the quarter ended in September - Earnings Summary6
Seite:  Weiter >>
35 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,8